These results suggested that A‐1 treatment improved mitochondrial function by activating AMPK/SIRT1/PGC‐1α, which in turn increased mitochondrial biogenesis and further delayed the progression of ALS disease. This evidence concerns the gene PPARGC1A and amyotrophic lateral sclerosis.